Report Sections

See All Reports

  • HP:0100512: Low levels of vitamin D
  • Pneumonia (382) Neoplasm (47) Respiratory tract infection (46) Diabetes mellitus (39) Abnormality of the cardiovascular system (39) Depressivity (35) Abnormal lung morphology (33) Hypoxemia (30) Acute kidney injury (29) Hypertension (25) Thromboembolism (23) Myocardial infarction (22) Anosmia (21) Mental deterioration (21) Arthritis (20) Type II diabetes mellitus (20) Chronic pulmonary obstruction (19) Leukemia (18) Pulmonary fibrosis (18) Pulmonary obstruction (18) Abnormality of the kidney (17) Stroke (17) Congestive heart failure (16) Abnormality of coagulation (16) Pulmonary embolism (16) Neoplasm of the lung (16) Rheumatoid arthritis (15) Asthma (15) Interstitial pneumonitis (15) Crohn's disease (15) Autistic behavior (14) Chronic pain (14) Type I diabetes mellitus (13) Deep venous thrombosis (12) Ulcerative colitis (12) Autism (11) Obesity (11) Respiratory distress (11) Colitis (11) Carcinoma (11) Alzheimer disease (10) Lymphoma (10) Chronic kidney disease (10) Myocarditis (10) Low levels of vitamin D (10) Sepsis (10) Renal insufficiency (9) Dementia (9) Abnormality of the liver (9) Coronary artery atherosclerosis (9) Weight loss (9) Inflammation of the large intestine (9) Pulmonary insufficiency (9) Behavioral abnormality (8) Psychosis (8) Infertility (8) Abnormality of the gastrointestinal tract (8) Migraine (7) Breast carcinoma (7) Psoriasiform dermatitis (7) Peripheral arterial stenosis (7) Fatigue (7) Schizophrenia (7) Encephalopathy (6) Lymphopenia (6) Dysphagia (6) Bronchiectasis (6) Immunodeficiency (6) Systemic lupus erythematosus (6) Osteoarthritis (6) Obstructive sleep apnea (6) Sleep apnea (6) Prostate cancer (6) Non-small cell lung carcinoma (6) Neoplasm of the large intestine (6) Seizure (5) Premature birth (5) Difficulty walking (5) Gastroparesis (5) Neoplasm of the pancreas (5) Autoimmunity (5) Knee osteoarthritis (5) Disseminated intravascular coagulation (5) Lymphoid leukemia (5) Inflammatory abnormality of the skin (5) Neoplasm of head and neck (5) Allergy (5) Eczema (4) Atopic dermatitis (4) Hepatic fibrosis (4) Cardiac arrest (4) Abnormality of blood and blood-forming tissues (4) Pulmonary arterial hypertension (4) Abnormal intestine morphology (4) Headache (4) Colon cancer (4) Reduced factor VIII activity (4) Malnutrition (4) Paroxysmal atrial fibrillation (4) Renal cell carcinoma (4) Abnormal anterior horn cell morphology (4) Attention deficit hyperactivity disorder (4) Amyotrophic lateral sclerosis (4) Arrhythmia (4) Endometriosis (4) Addictive behavior (4) Hypercoagulability (4) Insomnia (4) Abnormality of the eye (3) Obsessive-compulsive behavior (3) Abnormality of the endocrine system (3) Spastic diplegia (3) Polyneuropathy (3) Meningitis (3) Hepatic steatosis (3) Abnormal heart morphology (3) Cardiomyopathy (3) Tachycardia (3) Fever (3) Hypothermia (3) Apnea (3) Celiac disease (3) Myelodysplasia (3) Acute myeloid leukemia (3) Myeloproliferative disorder (3) Chronic lymphatic leukemia (3) Multiple myeloma (3) Cystoid macular edema (3) Postprandial hyperglycemia (3) Cutaneous melanoma (3) Small cell lung carcinoma (3) Pulmonary edema (3) Ovarian neoplasm (3) Neuroendocrine neoplasm (3) Bulimia (3) Hypogeusia (2) Hearing impairment (2) Visual impairment (2) Conjunctivitis (2) Cataract (2) Uveitis (2) Periodontitis (2) Agoraphobia (2) Nephrolithiasis (2) Abnormality of the thyroid gland (2) Abnormality of the skin (2) Jaundice (2) Lymphedema (2) Keratoconjunctivitis sicca (2) Spasticity (2) Hemiparesis (2) Abnormal joint morphology (2) Aortic valve stenosis (2) Angina pectoris (2) Pancreatitis (2) Thrombocytopenia (2) Autoimmune thrombocytopenia (2) Gout (2) Diarrhea (2) Gastroesophageal reflux (2) Neurodegeneration (2) Alopecia of scalp (2) Mutism (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Hypotension (2) Atherosclerosis (2) Hypoventilation (2) Squamous cell carcinoma (2) Male infertility (2) Back pain (2) Low back pain (2) Muscular dystrophy (2) Stillbirth (2) Chronic bronchitis (2) Lymphoproliferative disorder (2) Intervertebral disc degeneration (2) Stomatitis (2) Stridor (2) Hemeralopia (2) Arteritis (2) Hepatitis (2) Glioblastoma multiforme (2) B-cell lymphoma (2) Myeloid leukemia (2) Bronchitis (2) Pain (2) Cervix cancer (2) Cholangitis (2) Endocarditis (2) Toxemia of pregnancy (2) Myositis (2) Mania (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Otitis media (1) Conductive hearing impairment (1) Amblyopia (1) Abnormality of the nervous system (1) Aggressive behavior (1) IgA deposition in the glomerulus (1) Oligospermia (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Urticaria (1) Angiokeratoma corporis diffusum (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Syncope (1) Cerebral hemorrhage (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Premature rupture of membranes (1) Iron deficiency anemia (1) Anemia (1) Dehydration (1) Constipation (1) Anorexia (1) Esophageal varix (1) Chorea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Abnormality of the spinal cord (1) Hyperkalemia (1) Memory impairment (1) Encephalitis (1) Spina bifida (1) Language impairment (1) Myelomeningocele (1) Waddling gait (1) Increased intracranial pressure (1) Biliary cirrhosis (1) Vascular dilatation (1) Recurrent E. coli infections (1) Osteomyelitis (1) Tachypnea (1) Central apnea (1) Embryonal neoplasm (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Allergic rhinitis (1) Skeletal muscle atrophy (1) Spondylolisthesis (1) Myalgia (1) Bruxism (1) Neonatal death (1) Increased body weight (1) Enterocolitis (1) Intermittent claudication (1) Thrombophlebitis (1) Supraventricular tachycardia (1) Ventricular tachycardia (1) Acute myelomonocytic leukemia (1) Dilatation of the cerebral artery (1) Coronary artery stenosis (1) Spontaneous abortion (1) Venous insufficiency (1) Monoclonal immunoglobulin M proteinemia (1) Abnormality of bone marrow cell morphology (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Bladder neoplasm (1) Uterine neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Placental abruption (1) Sinus tachycardia (1) Bronchiolitis (1) Erythroid hypoplasia (1) Asterixis (1) Hodgkin lymphoma (1) Ciliary dyskinesia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Rhinitis (1) Seasonal allergy (1) Hypercapnia (1) Restless legs (1) Non-Hodgkin lymphoma (1) Membranous nephropathy (1) Retinal vein occlusion (1) Vasovagal syncope (1) Heart block (1) Cough (1) Neonatal asphyxia (1) Dyspareunia (1) Ductal carcinoma in situ (1) Heart murmur (1) Cardiogenic shock (1) Cholangiocarcinoma (1) Vulvar neoplasm (1) Brain neoplasm (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Abnormality of movement (1) Sarcoma (1) Subdural hemorrhage (1) Biliary tract neoplasm (1) Nasal polyposis (1) Rectal fistula (1) Eclampsia (1) Esophagitis (1) Vaginal neoplasm (1) Cellulitis (1) Angioedema (1) Self-injurious behavior (1) Gastrointestinal stroma tumor (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Halitosis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0100512: Low levels of vitamin D

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (21)


    Name (Synonyms) Correlation
    drug672 Bolus vitamin D3 Wiki 0.32
    drug1897 High nitrite/NDMA meals Wiki 0.32
    drug1246 Daily placebo Wiki 0.32
    Name (Synonyms) Correlation
    drug3950 Serum zinc, vitamin d vitamin b12 levels . Wiki 0.32
    drug4501 Treatment as usual vitamin D Wiki 0.32
    drug3985 Single high dose vitamin D Wiki 0.32
    drug385 Aspirin 81 mg Wiki 0.32
    drug671 Bolus placebo Wiki 0.32
    drug2415 Low nitrite/NDMA meals Wiki 0.32
    drug3575 Ranitidine Wiki 0.32
    drug4693 Vitamin D 1000 IU Wiki 0.32
    drug1245 Daily Vitamin D3 Wiki 0.32
    drug806 COVID-19 IgG/IgM Rapid Test Cassette test (Healgen Scientific, Houston, Texas, USA) Wiki 0.32
    drug3518 RAPA-501-Allo off-the-shelf Therapy of COVID-19 Wiki 0.32
    drug4692 Vitamin D Wiki 0.19
    drug2150 Interferon Beta-1B Wiki 0.18
    drug2149 Interferon Beta-1A Wiki 0.16
    drug2366 Lopinavir / Ritonavir Wiki 0.14
    drug4694 Vitamin D3 Wiki 0.13
    drug3195 Placebo Wiki 0.05
    drug1950 Hydroxychloroquine Wiki 0.03

    Correlated MeSH Terms (9)


    Name (Synonyms) Correlation
    D014808 Vitamin D Deficiency NIH 0.90
    D058345 Asymptomatic Infections NIH 0.22
    D004211 Disseminated Intravascular Coagulation NIH 0.14
    Name (Synonyms) Correlation
    D003141 Communicable Diseases NIH 0.06
    D012141 Respiratory Tract Infections NIH 0.05
    D007239 Infection NIH 0.04
    D018352 Coronavirus Infections NIH 0.03
    D014777 Virus Diseases NIH 0.03
    D045169 Severe Acute Respiratory Syndrome NIH 0.03

    Correlated HPO Terms (2)


    Name (Synonyms) Correlation
    HP:0005521 Disseminated intravascular coagulation HPO 0.14
    HP:0011947 Respiratory tract infection HPO 0.05

    Clinical Trials

    Navigate: Correlations   HPO

    There are 10 clinical trials


    1 The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations

    Although the novel SARS-CoV-2 virus (COVD-19) is classified as an acute respiratory infection, emerging data show that morbidity and mortality are driven by disseminated intravascular coagulopathy. Untreated CAC leads to microangiopathic thromboses, causing multiple systems organ failure and consuming enormous healthcare resources. Identifying strategies to prevent CAC are therefore crucial to reducing COVID-19 hospitalization rates. The pathogenesis of CAC is unknown, but there are major overlaps between severe COVID-19 and vitamin D insufficiency (VDI). We hypothesize that VDI is a major underlying contributor to CAC. Preliminary data from severe COVID-19 patients in New Orleans support this hypothesis. The purpose of the proposed multi-center, prospective, randomized controlled trial is to test the hypothesis that low-risk, early treatment with aspirin and vitamin D in COVID-19 can mitigate the prothrombotic state and reduce hospitalization rates.

    NCT04363840
    Conditions
    1. COVID
    2. Vitamin D Deficiency
    3. Coagulopathy
    4. Disseminated Intravascular Coagulation
    Interventions
    1. Drug: Aspirin 81 mg
    2. Dietary Supplement: Vitamin D
    MeSH:Disseminated Intravascular Coagulation Vitamin D Deficiency
    HPO:Disseminated intravascular coagulation Low levels of vitamin D

    Primary Outcomes

    Description: Hospitalization for COVID-19 symptoms

    Measure: Hospitalization

    Time: 2 weeks
    2 Investigating the Role of Vitamin D in the Morbidity of COVID-19 Patients

    The 2019 novel coronavirus disease (COVID-2019) pandemic is an enormous health issue of worldwide scale. Prevention and/or treatment with a widely-available and already-licensed product such as vitamin D (cholecalciferol) could have a large impact on healthcare worldwide. Given ethnic variation in vitamin D production, this could help to address the discrepancies in how people of different ethnicities are affected by COVID-19. There are currently no published studies analysing either individual-level evidence on the effect of vitamin D status on COVID-19 outcomes, or any prospective studies planning on following-up patients with reference to vitamin D and COVID-19 infection. The study will have 2 arms. Arm 1 will recruit patients hospitalised with COVID-19. Vitamin D levels will be measured in these patients and compared with outcome measures of COVID-19 severity. In Arm 2, patients will be recruited prospectively from local general practices (GPs) with measurement of vitamin D levels at enrolment. They will be followed up after 6 months to determine whether baseline vitamin D levels correspond with developing COVID-19. Data will be collected from a mixture of patient medical records, electronic patient records, laboratory data and from patients themselves. Data in Arm 1 will be analysed with a combination of linear and logistic regression, as appropriate, and with adjustment for covariates. Data in Arm 2 will be analysed as a case-control study, with adjustment for covariates. The primary objectives are to determine whether vitamin D levels affect outcomes in COVID-19 infection and whether vitamin D deficiency is associated with increased risk.

    NCT04386044
    Conditions
    1. COVID-19
    2. Vitamin D Deficiency
    MeSH:Vitamin D Deficiency
    HPO:Low levels of vitamin D

    Primary Outcomes

    Description: Development of COVID-19 during case-control study

    Measure: COVID-19 infection

    Time: 1 year

    Description: Whether hospitalised COVID-19 patients require oxygen therapy

    Measure: Oxygen therapy for COVID-19

    Time: 1 year

    Description: Whether patients hospitalised with COVID-19 were discharged

    Measure: Discharge following COVID-19 hospitalisation

    Time: 1 year

    Description: Whether patients hospitalised with COVID-19 died in hospital

    Measure: Death due to COVID-19

    Time: 1 year
    3 Cohort Study to Determine the Association Between Vitamin D Deficiency and Severity of the Disease in Patients With Coronarvirus Disease 2019 (COVID-19)

    In this prospective observational study we aim to study the association of vitamin D deficiency with adverse clinical outcomes in patients infected with Coronavirus disease 2019

    NCT04403932
    Conditions
    1. Coronavirus Disease 2019 (COVID-19)
    MeSH:Coronavirus Infections Vitamin D Deficiency
    HPO:Low levels of vitamin D

    Primary Outcomes

    Description: death, admission to the intensive care unit, and/or a need for higher oxygen flow than that provided by nasal cannula

    Measure: severe COVID-19

    Time: 17/04/2020 to 01/06/2020
    4 Vitamin D Testing and Treatment for Adults With COVID 19

    This study will measure vitamin D levels in adults with COVID 19. Participants with low levels of vitamin D will be entered into an open label trial of supplementation with vitamin D.

    NCT04407286
    Conditions
    1. Covid 19
    2. Vitamin D Deficiency
    Interventions
    1. Dietary Supplement: Vitamin D3
    MeSH:Vitamin D Deficie Vitamin D Deficiency
    HPO:Low levels of vitamin D

    Primary Outcomes

    Description: change in level of Vitamin D, 25-Hydroxy between the two time points

    Measure: Vitamin D levels

    Time: baseline and after two weeks of vitamin D supplementation

    Description: We will calculate the change in severity of COVID 19 symptoms from baseline to 2 weeks after vitamin D supplementation

    Measure: severity of COVID 19 symptoms

    Time: baseline and at 2 weeks after vitamin D supplementation
    5 Vitamin D Testing and Treatment for Adults With COVID 19

    This study will measure vitamin D levels in adults with COVID 19. Participants with low levels of vitamin D will be entered into an open label trial of supplementation with vitamin D.

    NCT04407286
    Conditions
    1. Covid 19
    2. Vitamin D Deficiency
    Interventions
    1. Dietary Supplement: Vitamin D3
    MeSH:Vitamin D Deficie Vitamin D Deficiency
    HPO:Low levels of vitamin D

    Primary Outcomes

    Description: change in level of Vitamin D, 25-Hydroxy between the two time points

    Measure: Vitamin D levels

    Time: baseline and after two weeks of vitamin D supplementation

    Description: We will calculate the change in severity of COVID 19 symptoms from baseline to 2 weeks after vitamin D supplementation

    Measure: severity of COVID 19 symptoms

    Time: baseline and at 2 weeks after vitamin D supplementation
    6 Zinc Vitamin D and b12 Levels in the Covid-19 Positive Pregnant Women

    Zinc d vitamin and b12 serum levels in covid-19 positive pregnants will be compared in terms of patients' responses to computed tomography and treatment.

    NCT04407572
    Conditions
    1. COVID
    2. Zinc Deficiency
    3. Vitamin D Deficiency
    Interventions
    1. Other: Serum zinc, vitamin d vitamin b12 levels .
    MeSH:Vitamin D Deficiency
    HPO:Low levels of vitamin D

    Primary Outcomes

    Description: Serum zinc, vitamin d vitamin b12 levels of 45 patients will be measured and evaluated together with the information of the patients.

    Measure: Serum zinc, vitamin d vitamin b12 deficiency levels

    Time: 2 months
    7 Reducing Asymptomatic Infection With Vitamin D in Coronavirus Disease

    This study is intended to address whether oral daily vitamin D supplementation reduces infection with SARS-CoV-2 in healthy young adults. The primary aim of the study is to demonstrate a reduction in 'silent' seroconversion rates, consistent with asymptomatic transmission of SARS-CoV-2, in a young healthy adult population following 24 weeks of taking oral vitamin D supplemented at a dose of 1000 I.U. daily, versus matching placebo. The secondary aims of this study are to explore: 1. Any effect on symptomatic illness. 2. The background 'point' prevalence and subsequent rate of increase in seropositivity for SARS-CoV-2 in healthy young adults. 3. The individual reductions in seropositivity to SARS-CoV-2 over time, and changes in seropositivity in a defined young adult population over time. 4. Where salivary Immunoglobulin A (IgA) may be used to provide an alternative/ complementary serological method 5. The effect (if any) of vitamin D supplementation on seroconversion rates stratified by: i) level of baseline vitamin D 'deficiency/ insufficiency/ sufficiency' status; ii) extent of BMI-defined normal/overweight/obesity cut-offs and iii) gender.

    NCT04476680
    Conditions
    1. SARS-CoV Infection
    2. Vitamin D Deficiency
    3. Covid19
    4. Acute Respiratory Tract Infection
    Interventions
    1. Dietary Supplement: Vitamin D 1000 IU
    2. Drug: Placebo
    MeSH:Infection Communicable Diseases Respiratory Tract Infections Coronavirus Infections Severe Acute Respiratory Syndrome Vitamin D Deficiency Asymptomatic Infections
    HPO:Low levels of vitamin D Respiratory tract infection

    Primary Outcomes

    Description: asymptomatic seroconversion for SARS-CoV-2

    Measure: Seroconversion

    Time: 24 weeks

    Description: asymptomatic seroconversion for SARS-CoV-2

    Measure: Interim analysis - seropositivity at 12 weeks

    Time: 12 weeks

    Secondary Outcomes

    Description: Sensitivity and specificity of dried blood spot assay compared with venous blood serology

    Measure: Dried Blood Spot performance

    Time: 24 weeks

    Description: Sensitivity and specificity of salivary IgA compared with venous blood serology

    Measure: Salivary IgA performance

    Time: 24 weeks

    Description: The background 'point' prevalence and subsequent rate of increase in seropositivity for SARS-CoV-2 in healthy young adults.

    Measure: Prevalence of SARS-CoV-2

    Time: 24 weeks

    Description: The individual reductions in seropositivity to SARS-CoV-2 over time, and changes in seropositivity in a defined young adult population over time

    Measure: Change in seropositivity

    Time: 24 weeks

    Description: The effect of vitamin D supplementation on seroconversion rates stratified by: i) level of baseline vitamin D 'deficiency/ insufficiency/ sufficiency' status; ii) extent of BMI-defined normal/overweight/obesity cut-offs, iii) gender iv) ethnicity

    Measure: Change in seroconversion rate

    Time: 24 weeks
    8 The Role of Vitamin D in Mitigating COVID-19 Infection Severity: Focusing on Reducing Health Disparities in South Carolina

    The purpose of this study is to evaluate how useful vitamin D supplementation is in reducing the severity of COVID-19 symptoms and the body's inflammatory and infection-fighting response to COVID-19. Individuals ≥50 years of age and older who are tested for COVID-19 and negative will be randomized (like flipping a coin) to either daily high dose vitamin D supplementation (6000 IU vitamin D3/day) vs. standard of care. Those individuals ≥50 years of age or older who test positive for COVID-19 at baseline will be randomized to bolus vitamin D (20,000 IU/day for 3 days) followed by high dose (6000 IU vitamin D/day) vs. standard of care for 12 months. All participants will receive a multivitamin containing vitamin D.

    NCT04482673
    Conditions
    1. COVID-19
    2. Vitamin D Deficiency
    3. Respiratory Viral Infection
    Interventions
    1. Drug: Daily Vitamin D3
    2. Drug: Daily placebo
    3. Drug: Bolus vitamin D3
    4. Drug: Bolus placebo
    MeSH:Infection Communicable Diseases Virus Diseases Vitamin D Deficiency
    HPO:Low levels of vitamin D

    Primary Outcomes

    Description: metabolite of vitamin D

    Measure: Change in total circulating 25(OH)D concentration

    Time: monthly in COVID-19 negative participants through study completion for 1 year

    Description: metabolite of vitamin D

    Measure: Change in total circulating 25(OH)D concentration in COVID-19 positives

    Time: baseline, 2 and 4 weeks, then months 3, 6, 9 and 12 in COVID-19 positive participants

    Description: The presence or absent of SARS-CoV-2 antibody will be measured at baseline, 3, 6, 9 and 12 months.

    Measure: Change in SARS-CoV-2 antibody titers

    Time: every 3 months up to 12 months

    Secondary Outcomes

    Description: At baseline, 3, 6, 9 and 12 months, inflammatory cytokines will be measured in participant plasma samples. Cytokines to be measured are Interferon-gamma (IFN-g), Interleukin-1beta (IL-1B), IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-13, and Tumor Necrosis Factor-alpha (TNFa). Values of these cytokines at baseline will compared to those at 3, 6, 9, and 12 months

    Measure: Change in inflammatory cytokine concentration (10 cytokine panel Elisa: Interferon (INF)-gamma, Interleukin (IL)-1beta, IL-2, IL-3, IL-4, IL-6, IL-8, IL-10, IL-13, Tumor Necrosis Factor (TNF)-alpha

    Time: baseline and every 3 months up to 12 months

    Description: COVID-19 positive participants or if COVID-19 negatives develop respiratory symptoms will complete this respiratory survey daily for 2 weeks

    Measure: Respiratory symptoms

    Time: daily for 2 weeks

    Description: Inventory of signs and symptoms of rhino/sinusitis. These signs include sneezing, running nose, cough, dizziness, fatigue, and sense of smell. Each sign is rated on a scale of 0 to 5, with 0 indicating not problem, for instance 1 indicating mild problem, 4 indicating severe problem and 5 indicating problem as bad as it can be.

    Measure: Signs and symptoms of rhino/sinusitis

    Time: Baseline then 3, 6, 9 and 12 months in negatives and daily for 2 weeks in positives

    Description: Dietary intake assessment

    Measure: NCI Dietary Intake

    Time: baseline then at 6 and 12 months

    Description: Survey of participant health problems

    Measure: Charlson Comorbidity survey

    Time: baseline then at 6 and 12 months

    Description: Assessment of physical activity of each participant

    Measure: Paffenberger Physical Activity Assessment

    Time: Baseline then at 6 and 12 months

    Description: Each participant will complete the Perceived Stress Scale Questionnaire (PSS) to assess their perceived stress. Assessments are base on a scale of 0 to 4, with 0 indicating "never" and 4 indicating "very often"

    Measure: Perceived stress

    Time: monthly for 1 year

    Description: Each participant will complete the and Pandemic Stress Index Questionnaire (PSI) to assess their perceived stress cause by the pandemic. Assessments are base on a scale of 0 to 6, with 0 indicating "not at all" and 5 indicating "extremely," and 6 indicating "decline to answer."

    Measure: Pandemic stress

    Time: monthly for 1 year

    Description: Personality characteristics of each participant

    Measure: NEO-Personality Inventory

    Time: baseline visit

    Description: A health assessment will be completed by each participant monthly for 1year. This health. This is for information on health status only and not for comparative assessment.

    Measure: GrassrootsHealth Monthly Health assessment

    Time: baseline, 6, and 12 months
    9 High Dose Vitamin-D Substitution in Patients With COVID-19: a Randomized Controlled, Multi Center Study

    The world is currently facing a pandemic with the coronavirus (SARS-CoV-2) which leads to the disease of COVID-19. Risk factors for a poor outcome of COVID-19 have so far been identified as older age and co-morbidity including chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD) and current smoking status. Previous studies found, that vitamin D deficiency is more prevalent among patients with these risk factors. There are observational studies reporting independent associations between low serum concentrations of 25-hydroxyvitamin D (the major circulating vitamin D metabolite) and susceptibility to acute respiratory tract infection. Vitamin D substitution in patients with COVID-19 who show a vitamin D deficiency should therefore be investigated for efficacy and safety. The study is designed as a randomized, placebo-controlled, double blind study. The objective of the study is to test the hypothesis that patients with vitamin D deficiency suffering from COVID-19 treated under standardized conditions in hospital will recover faster when additionally treated with a single high dose of vitamin D compared to standard treatment only.

    NCT04525820
    Conditions
    1. Covid19
    2. Vitamin D Deficiency
    3. Corona Virus Infection
    4. ARDS
    5. Coronavirus
    6. SARS-CoV Infection
    Interventions
    1. Drug: Single high dose vitamin D
    2. Drug: Placebo
    3. Drug: Treatment as usual vitamin D
    MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome Vitamin D Deficiency
    HPO:Low levels of vitamin D

    Primary Outcomes

    Description: Overall duration of the hospitalization from day of admission until the day of discharge or fatality

    Measure: Length of hospitalization

    Time: Administration to Discharge from hospital care (mean duration is between 14 and 22 days for Patients with COVID 19)

    Secondary Outcomes

    Description: Did the patient need a intensive care treatment during the hospitalization (yes/no)

    Measure: Need of intensive care

    Time: Until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID-19)

    Description: Day of admission to ICU until discharge or fatality

    Measure: Lenght of the Intensive Care Treatment

    Time: Until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID-19)

    Description: Percentage of patient died during hospitalization

    Measure: Overall mortality

    Time: During the length of hospitalisation (mean duration is between 14 and 22 days for Patients with COVID-19)

    Description: percentage of patients with 25-hydroxyvitamin D > 50nmol/L (>20ng/mL) at day 7 - The values of calcium, phosphorus, 24-hydroxyvitamin D, 1.25-dihydroxyvitamin D, parathyroid hormone.

    Measure: Development of vitamin D levels

    Time: Day 1 (Baseline) and Day 7 after the first administration of the high dose vitamin D or the placebo and at discharge (mean hospital stay is between 14 and 22 days for Patients with COVID-19)

    Description: percentage of patients developing a sepsis

    Measure: Development of sepsis

    Time: During the length of hospitalization (mean duration is between 14 and 22 days for Patients with COVID-19)

    Other Outcomes

    Description: We assess every other complications which occurs due to COVID-19

    Measure: Complications due to COVID-19

    Time: During the length of hospitalization (mean duration is between 14 and 22 days for Patients with COVID-19)

    Description: The BP will be assessed daily in mmHg

    Measure: Blood pressure (BP)

    Time: Daily until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID-19)

    Description: The heart rate will be assessed daily in bpm

    Measure: Heart rate

    Time: Daily until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID-19)

    Description: The SpO2 will be assessed daily in %

    Measure: Peripheral oxygen saturation (SpO2)

    Time: Daily until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID 19)

    Description: Requirement for oxygen will be assessed daily (yes/no) if yes how many liters per minute

    Measure: Percentage of patients who require oxygen

    Time: Daily until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID 19)

    Description: Breathing frequence will be assessed daily in breaths per minute

    Measure: Breathing frequency

    Time: Daily until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID 19)

    Description: GCS will be assessed daily 3 to 15 points. It describes the extent of impaired consciousness. 15 points means no impairment, 3 points means severe impairment of consciousness.

    Measure: Glasgow Coma Scale (GCS)

    Time: Daily until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID 19)

    Description: Assessing the history of smoking in pack years (PY). the assessment will be made with the following options for answering Current smoker: Smoking for how many years? Cigarettes per day? Former smoker, how many years smoked? How many cigarettes per day Life-long non-smoker

    Measure: Percentage of patients are smokers, former smokers or lifelong non-smokers

    Time: Assessing of the smoking Status at Basleine

    Description: Assessed in No/ Mild/ Moderate /Severe

    Measure: Current Symptoms

    Time: Daily until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID 19)

    Description: Temperature will be assessed daily in degrees celsius

    Measure: Temperature

    Time: Daily until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID 19)
    10 Baseline Vitamin D Deficiency and COVID-19 Disease Severity/Need for Escalation of Care

    It is known that vitamin D has been found to decrease incidence of viral respiratory infections, as well as have effects on multiple cytokines involved in immunomodulation and the bradykinin/renin-angiotensin system. Recently, data was released showing a correlation between baseline vitamin D deficiency status and increased risk of contracting COVID-19. Separate analysis shows that many of the deleterious effects of COVID-19 may be due to the bradykinin/RAS system, and that vitamin D is one plausible treatment option to modulate these effects. Studies are currently ongoing to determine if vitamin D supplementation of those hospitalized with COVID-19 has a beneficial effect on patient outcomes. Healthcare resources have been strained during the pandemic in areas of heavy caseload. It is possible that those with concurrent vitamin D deficiency and COVID positivity have an increased need for escalation of care. A small study has been conducted in this area, but was limited by small number of subjects.

    NCT04628000
    Conditions
    1. Vitamin D Deficiency
    2. Covid19
    Interventions
    1. Other: Vitamin D
    MeSH:Vitamin D Deficiency
    HPO:Low levels of vitamin D

    Primary Outcomes

    Description: Length of stay

    Measure: LOS duration in days

    Time: 3/9-9/7 2020

    Description: Supplemental Oxygen need

    Measure: Supp O2 flow volume in L/min

    Time: 3/9-9/7 2020

    HPO Nodes


    Reports

    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook